Arcturus (ARCT) Q2 2026 earnings review
A Major Pivot: CSL Exits, Rare Disease Focus Intensifies
Arcturus is undergoing a fundamental transition. The massive 89% YoY revenue drop to $3.0M marks the bitter end of its infectious disease collaboration with CSL Seqirus. While management spins 'regaining strategic control' of its COVID/flu vaccines as a positive, the reality is a stark loss of their primary revenue engine. However, the company has successfully pivoted to defense: aggressive R&D cuts (-41% YoY) and a new strategic collaboration with Thermo Fisher for its Cystic Fibrosis (CF) program have secured the cash runway through the end of 2028. Arcturus is now purely a rare disease, clinical-stage biotech with two major catalysts on the immediate horizon.
🐂 Bull Case
The new collaboration with Thermo Fisher Scientific for ARCT-032 (Cystic Fibrosis) provides critical Phase 3 manufacturing and clinical research support, alleviating a massive capital expenditure burden.
Despite the revenue collapse, aggressive cost-cutting and a $12M settlement from CSL have extended the cash runway through year-end 2028, ensuring funding past key regulatory catalysts.
🐻 Bear Case
The termination of the CSL Seqirus partnership removes Arcturus's primary near-term revenue stream and casts severe doubt on the global commercial viability of the KOSTAIVE vaccine outside of Japan.
With collaboration revenue evaporating, Net Loss widened by 158% YoY to $23.8M. The company must now rely entirely on its cash reserves to fund operations until a new partner is secured or a rare disease drug is approved.
⚖️ Verdict: ⚪
Neutral. The financial shock of losing CSL was largely anticipated given prior US regulatory delays. The Thermo Fisher deal is a major strategic win that stabilizes the ship, but the company's valuation now rests entirely on unproven Phase 2 rare disease assets.
Key Themes
The CSL Divorce: Narrative vs Data
Management stated they are 'pleased to regain strategic control of KOSTAIVE' to 'increase the value of our validated sa-mRNA vaccine platform.' The data sharply contradicts this positive spin. Collaboration revenue decelerated from $138M in FY24 to just $3.0M this quarter. The settlement provides a meager $12M cash payment and $16M in liability relief—a fraction of the lost milestone potential. Arcturus now faces the daunting task of monetizing its infectious disease portfolio alone in a challenging post-pandemic market.
Thermo Fisher Partnership Secures CF Future
In a critical de-risking move, Arcturus secured Thermo Fisher to run Phase 3 clinical research (via PPD) and manufacturing for ARCT-032. If approved, Thermo Fisher gets exclusive commercial manufacturing rights. This shifts heavy capital requirements off Arcturus's balance sheet, preserving cash while advancing a complex inhaled mRNA therapeutic.
ARCT-810 (OTC) Catalyst Approaching
The Phase 2 study for OTC deficiency is now fully enrolled and dosed. Data and the subsequent regulatory plan will be communicated in Q3 2026. This represents the most immediate value inflection point for the company's LUNAR lipid-mediated delivery technology in liver targets.
ARCT-032 Phase 3 Decision Timeline Set
The 12-week open-label Phase 2 CF study is progressing on schedule across the US, Israel, and Turkey. A formal decision to advance into Phase 3 is slated for Q4 2026. The ability to dose beyond one month utilizing the proprietary LUNAR platform remains a key technological differentiator versus failed competitor programs.
Regulatory Macro Headwinds for Vaccines
The underlying cause of the CSL partnership failure traces back to sudden shifts in the FDA's regulatory stance on COVID-19 vaccines (noted in previous quarters), which indefinitely delayed the US BLA. These persistent macro-level regulatory hurdles significantly impair Arcturus's ability to easily secure a new partner for KOSTAIVE in western markets.
Inherent Risks in Open-Label Trial Design
The critical ARCT-032 Phase 2 CF study remains open-label. Without a concurrent placebo control, interpreting highly variable lung function data (FEV1, LCI) relies heavily on historical baselines and external natural history datasets. This structural trial weakness heightens the risk of regulatory pushback during the planned Phase 3 transition.
Other KPIs
Decelerating sharply. R&D expenses dropped 41% YoY from $29.6M in 25Q2. This massive reduction reflects the wind-down of the infectious disease pipeline and a disciplined capital reallocation exclusively toward the CF and OTC rare disease programs.
Stable trajectory given the circumstances. Down $39.4M from December 31, 2025 ($230.9M), indicating an average quarterly cash burn of ~$19.7M. The recent $12M injection from CSL will further buffer the balance sheet in Q3.
Guidance
Accelerating/Improving. Management previously guided a runway 'beyond Q2 2028.' The extension to year-end 2028 reflects the impact of the $12M CSL settlement, R&D liability releases, and the Thermo Fisher cost-sharing dynamic. This is sufficient to read out Phase 2 data for both core programs and potentially initiate pivotal trials.
The company expects to report Phase 2 data and layout the End-of-Phase 2 FDA meeting strategy (targeting adult and pediatric paths) next quarter.
The go/no-go decision for the pivotal Cystic Fibrosis trial will be finalized by the end of the year, triggering massive resource deployment from new partner Thermo Fisher if successful.
Key Questions
Financial Mechanics of the Thermo Fisher Deal
How much of the Phase 3 clinical trial and manufacturing costs will Thermo Fisher shoulder directly, and what economic concessions (royalties/margins) were traded to secure this?
KOSTAIVE Ex-Japan Monetization
With CSL exiting the partnership, are you actively seeking a new commercial partner for the US/EU markets for KOSTAIVE, or is the infectious disease portfolio being effectively shelved outside of the Meiji JV in Japan?
OTC Data Efficacy Bar
As ARCT-810 data approaches in Q3, what specific threshold of ammonia/glutamine biomarker reduction does management view as necessary to secure FDA blessing for a pediatric pivotal trial?